skip to main page content
Twitter LinkedIn

FULLY SUBSCRIBED: Within the Walls at Wilton - the home of business and science in the Tees Valley

Thursday, 21st March 2019, 18:00 to 20:30

Venue : The Wilton Centre, Wilton, Nr Redcar TS10 4RF

In Partnership with:

Our March event gives members and guests an opportunity to take a closer look within the Walls of the Wilton Centre, a business and science hub close to Redcar set in a 75 acre landscaped park with its own lake.

Wilton is home to over 60 companies of all sizes, including a number of national and global businesses that have their UK headquarters there.

Tees Valley Business Club Chair, Jane Reynolds, will invite a panel of resident businesses – one large, one medium and one small - to speak about their businesses and experiences in Wilton.

There are limited places for this event so early booking is recommended.

Running order for the evening is as follows:

6.00pm Registration with Tea/Coffee, light supper and open networking
6.30pm Welcome and introduction from TVBC
6.40pm Wilton Business Panel with Jane Reynolds and:-
             - Nick Hutchinson, Saturn Business Unit Lead, FUJIFILM Diosynth Biotechnologies
             - Catherine Bladen PhD, Director of Scientific Operations, Absolute Antibody Ltd
             - Dai Hayward, CEO, Micropore Technologies Ltd
7.40pm Business Card Exchange and Networking
8.30pm Event close

For directions use the link below:
https://www.wiltoncentre.com/location/

Attendance to this event is without charge for members and eligible guests*. Please bring plenty of business cards.

Member invitations will be issued by direct email.

Guest booking: We enable six guests to attend each of our events, with all places allocated on a first come first served basis. All guest places have been filled for this event. Please check our future events on our Club Events page for future dates.

Panel Member Biogs

Biog: Dai Hayward, CEO, Micropore Technologies Ltd

Dai’s career has been spent in performance chemicals and related businesses. He’s passionate about delivering business value by finding innovative solutions to industry problems through the application of chemistry.

Since joining Micropore in 2010 he has led the transition from an innovative lab-based technology with potential, to a practical, fully scalable, industrial product. 

Biog: Dr Catherine Bladen, Director of Scientific Operations 

Catherine has more than 15 years’ experience in biochemistry research (specifically protein identification, purification and characterization) both in the UK and in the USA. She completed her PhD in 2001 in the Cancer Research Unit at Newcastle University, studying novel proteins involved in p53 independent cancer pathways. From there, Catherine spent 6 years at the Medical College of Georgia (USA) identifying proteins involved in double stranded DNA repair as a consequence of medical radiation exposure (radiotherapy). Catherine then spent 7 years at Leeds University researching the role of DNA repair and oxidative stress in Osteoarthritis. A further two years were then spent at Newcastle University leading a large, multi-national research consortium identifying mutations leading to Duchenne Muscular Dystrophy in an effort to understand how mutation status and clinical outcomes were connected. Catherine joined Absolute Antibody in 2015 and heads up our research and production teams.

 

Biog: Nick Hutchinson, Saturn Business Unit Lead, FUJIFILM Diosynth Biotechnologies

Nick started his career by obtaining an Engineering Doctorate in Biochemical Engineering from UCL, London. He worked for a contract biomanufacturing organization in the south east, UK before making the north east his home ten years ago. Since returning to the north of England he was worked in marketing functions for three different suppliers to the biotech industry during which he completed his MBA from Durham University. Nick now leads the Saturn Business Unit for FUJIFILM Diosynth Biotechnologies based in the Wilton Centre where we perform the manufacturing process development of new monoclonal antibody therapeutics on behalf of our pharma and biotech clients.